ArticleCancer cell international2026
Novel a new prognostic model of thyroid carcinoma based on macrophage and cuproptosis-related lncRNA.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid carcinoma is a type of malignant tumor with a relatively good prognosis, but some types have a poorer prognosis. Therefore, it is necessary to establish a new prognostic model to predict the survival outcomes and immune therapy responses of thyroid cancer patients.
methodsScRNA analysis was conducted to identify cuproptosis-related genes and macrophages-related genes. The Wilcoxon algorithm was employed to identify tumor-related genes. The overlapping genes were utilized to identify lncRNAs that are related to both macrophages and cuproptosis. Lasso was used to construct a prognostic model. Based on the model, we conducted survival analysis, mutational profile analysis, and drug sensitivity analysis.
resultsOur prognostic risk model has identified 11 macrophage and cuproptosis-related lncRNAs. It has been confirmed that our prognostic model showed favorable performance in predicting the survival outcomes of patients in the TCGA-THCA cohort, with an AUC value exceeding 0.8, supporting its potential value for prognostic assessment of thyroid carcinoma. In this study, we observed no significant disparity in gene mutation rates between the high-risk and low-risk groups. Patients categorized in the low-risk group exhibit heightened sensitivity to immunotherapy and demonstrate responsiveness to a variety of immunotherapeutic agents, such as dasatinib.
conclusionOur study highlights the potential of macrophage and cuproptosis-related lncRNAs as novel predictive biomarkers for thyroid carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.